Latest bionic eye developments indicate bright future for ocular medical devices

The Alpha IMS implant features an array of photosensitive electrodes, which replace the function of damaged or dead cellular photoreceptors

bioniceye2

Photo Courtesy: www.techetron.com)

The recent announcement by the Clinical Ophthalmology Research Group at the University of Oxford that two patients were able to achieve some restoration of vision following implantation of the Alpha IMS device puts maker Retina Implant AG ahead of the pack in the bionic eye space, according to research and consulting firm GlobalData.

Mr Shashank Settipalli, GlobalData's Analyst covering Medical Devices, says: "These promising results, in conjunction with a string of positive developments for Retina Implant AG that included the CE mark and reimbursement approval in Germany for the first-generation Alpha IMS device, continue to bolster the company's standing in the burgeoning retinal prosthesis market."

The Alpha IMS implant features an array of photosensitive electrodes, which replace the function of damaged or dead cellular photoreceptors.

The device is implanted directly in the retina and is powered by a small, subcutaneous battery placed behind the ear.

The analyst continues: "Retina Implant AG's technology has distinct advantages over Second Sight, its biggest competitor in the retinitis pigmentosa space, and maker of the Argus II system, which was approved nearly half a decade ago to offer some relief from ocular problems caused by the condition.

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X